Acura NanoMedicine Corporation
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
Founded Year
2017
Unified Business No.
52805302
Status
Active
Number of Employees
4
Total Paid-in
Capital
25,014,700 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acura NanoMedicine is one of the few dual-platform technology new drug companies in the world. We integrate AI big data drug discovery platform and nano drug delivery system platform to develop a series of nano anticancer drugs (AN-8 series & others) that are highly effective to overcome a variety of difficult-to-treat cancers such as drug-resistant pancreatic cancer/brain cancer, etc. At the same time, we also use our platform technologies to cooperate with other new drug companies to form a joint development network for co-development new drugs.
